Research & emerging options
New and emerging treatments for canine IVDD
Some newer approaches are now used clinically in carefully selected dogs, while others remain research-only. The useful question is not whether a treatment sounds innovative, but what evidence supports it, which dogs were studied and whether pursuing it could delay established care.
How to read this guide
Separate current clinical options from experimental research
Neurological assessment, advanced imaging when indicated, medical management and decompressive surgery remain core pathways used according to the individual dog’s diagnosis and neurological status.
A treatment may be offered clinically at a specialist centre while still having a smaller evidence base and narrower eligibility than established pathways.
Research-led approaches should not be presented as proven alternatives or allowed to delay time-sensitive standard care.
Intradiscal chondroitinase at Cambridge
Percutaneous intradiscal chondroitinase
The Queen’s Veterinary School Hospital at the University of Cambridge currently offers chondroitinase injections as a treatment option for suitable dogs with IVDD. The enzyme is injected into selected intervertebral discs to break down disc material. Cambridge states that the procedure has been recognised as routine veterinary practice and can be offered outside the original trial, while eligible cases may also still enter an ongoing clinical trial.
Lower owner-reported recurrence in one retrospective cohort
A 2026 study compared 47 dogs treated with multidisc chondroitinase injections with 79 dogs receiving routine surgical management. All dogs included in the analysis had regained independent walking. Owner-reported recurrence of signs consistent with another disc herniation occurred in 6 of 47 chondroitinase-treated dogs (13%) and 24 of 79 surgical dogs (30%).
This does not mean chondroitinase guarantees a lower recurrence risk for an individual dog. The study was retrospective and non-randomised, recurrence was owner-reported, and the surgical group had variable numbers of fenestrated discs.
Chondroitinase for chronic spinal cord repair is a different research question
Researchers have also studied chondroitinase as part of regenerative strategies for chronic spinal cord injury, including olfactory ensheathing cells modified to produce chondroitinase ABC. That work is different from injecting enzyme into an intervertebral disc. The Royal Veterinary College describes this as clinical research, with variable and unpredictable improvement in earlier work.
Other areas researchers are exploring
Cell-based therapies
Mesenchymal stromal cells, olfactory ensheathing cells and related approaches have been investigated for spinal cord injury. Small samples and heterogeneous patients mean these should not be presented as established cures.
Biomaterials and regenerative scaffolds
Hydrogels and other materials are being studied as ways to support tissue repair or deliver therapies. Promising laboratory or early clinical work is a reason for further study, not proof of routine benefit.
Rehabilitation technologies
Locomotor training, underwater treadmill work, electrical stimulation and other approaches continue to be studied. Rehabilitation is widely used clinically, but the evidence and appropriate protocol differ between patient groups.
Other adjunctive approaches
Photobiomodulation, acupuncture, hypothermia, hyperbaric oxygen and neuroprotective drugs appear in the literature with varying evidence quality. They should not be grouped together as equally proven treatments.
Five questions to ask about any “breakthrough” treatment
1. Is it actually available?
Is this routine clinical care, a clinical research protocol or preclinical work?
2. Is there peer-reviewed evidence in dogs?
Ask for the study, not only a clinic headline, press release or social-media claim.
3. Which dogs were studied?
Neurological severity, lesion location, chronicity, breed, size and previous treatment can change relevance.
4. What was it compared with?
A result is easier to interpret when you know the comparator and whether the study was randomised, prospective or retrospective.
5. What could be lost by waiting?
For an acutely deteriorating dog, investigating a novel option should not delay assessment or treatment the veterinary team considers time-sensitive.
Protect the decision your dog needs today
If your dog is worsening, cannot walk, is paralysed, has severe pain or has a major new urinary problem, contact a veterinary professional urgently. Research options should not delay assessment, imaging or treatment recommended for the individual dog.
Trust & safety
Medical limitations & how this guide is prepared
Emerging research can be clinically useful without being universally appropriate. We separate current specialist availability from research findings and state important study limitations rather than turning group results into a personal prediction.
Medical limitations
Aubenord cannot determine whether an emerging therapy is safe, available or appropriate for your dog. Eligibility and timing require assessment by the veterinary team responsible for the case.
Research approach
We prioritise peer-reviewed canine studies, specialist consensus guidance and official hospital or research-centre information when discussing availability.
Evidence base
Sources & further reading
- Queen’s Veterinary School Hospital — current chondroitinase treatment information.
- Poacher J, Tammaro WJ, Jeffery ND, Freeman PM. 2026 recurrence comparison following multidisc ChABC injections or routine surgery.
- Olby et al. — ACVIM consensus statement on acute canine thoracolumbar disc extrusion.
- Royal Veterinary College — chronic spinal cord injury/chondroitinase research overview.
Evidence limit: the 2026 recurrence comparison was retrospective and non-randomised and included dogs that regained independent walking. It cannot establish the expected recurrence risk for every dog or prove superiority for all IVDD cases.